TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03006835

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clopidogrel

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clopidogrel

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clopidogrel

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clopidogrel
Study: NCT02350998

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OTO-201
Study: NCT06384703

Intervention type: DIAGNOSTIC_TEST
Intervention: Taking blood for kit study
Description: Taking blood for kit study (Elisa kit)

Intervention type: DIAGNOSTIC_TEST
Intervention: Taking blood for kit study
Description: Taking blood for kit study (Elisa kit)
Study: NCT01034215

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Envision the Rhythms of Life Program
Description: Patients learn to practice passive, active and targeted imagery for the purpose of improving mood state, modifying physiology (HRV, Body temperature, pain reduction) and also to mitigate the effects of their treatments, as defined by the IOM: chemo brain, fatigue, sleep deprivation, stress, anxiety, depression, and/or PTSD. Program is delivered with trainer present in the room.
Study: NCT04579419

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium Bicarbonate
Description: Botulinum Toxin diluted in Sodium Bicarbonate

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline
Description: 0.9 NaCl
Study: NCT01034215

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Envision the Rhythms of Life Program/Distance
Description: Patients learn to practice passive, active and targeted imagery for the purpose of improving mood state, modifying physiology (HRV, Body temperature, pain reduction) and also to mitigate the effects of their treatments, as defined by the IOM: chemo brain, fatigue, sleep deprivation, stress, anxiety, depression, and/or PTSD. Program is delivered by videoconference equipment
Study: NCT04848090

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Neonate WGS Testing
Description: Neonates will undergo whole genome sequencing, and analysis with a targeted panel of genes likely to cause genetic disorders in the first year of life. If no diagnosis is identified, sequenced data will be analyzed using a whole exome filter. Performed in a CLIA-certified lab. Pathogenic, likely pathogenic, and VUS in genes related to the phenotype will be returned to the care team and family.~Parents will be enrolled for the purpose of trio analysis with the child to assist in determining the pathogenicity of variants in genomic sequencing. Pathogenic and likely-pathogenic findings will be reported to the parents in the setting of genetic counseling.~Sibling will be enrolled and have samples collected for use in the genetic analysis only if deemed essential. Results will be reported to the parents in the setting of genetic counseling.
Study: NCT02302326

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Dose: metformin (1700 mg / day) for 12 weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Myo-inositol + folic acid
Description: Dose: Ovusitol® (4 g myo-inositol plus 400 micrograms of folic acid/day) for 12 weeks
Study: NCT02065804

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine
Description: injection, once, 5 min
Study: NCT01252303

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Nutrisystem
Description: Nutrisystem meal replacements for 12 weeks
Study: NCT02327559

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mind in Labor (MIL): Working with Pain in Childbirth
Description: The Mind in Labor (MIL) mindfulness intervention for pregnant women and their partners integrates mindfulness strategies for coping with labor pain and fear and formal mindfulness meditation with traditional childbirth education. The MIL intervention is held over 3 consecutive weekend days (Friday - Sunday) for a total of 16 hours of mindfulness skills training for childbirth preparation and labor pain management. Mindfulness strategies for coping with labor-related pain and fear are taught in an interactive, experiential format, with periods of didactic instruction.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as usual (TAU)
Description: The treatment as usual TAU active comparison condition includes participation in a standard care childbirth education course, chosen by participants in the TAU arm from a pre-approved list of hospital- and community-based childbirth education courses comparable in length and quality to MIL, but without any mindfulness meditation, mindful movement/yoga, or other core mind/body component (e.g., hypnosis).
Study: NCT02022150

Intervention type: BEHAVIORAL
Intervention: Body composition in paracentesis
Description: Takin blood samples and bioelectrical impedance measurmeent, Neuropsychological tests evaluation
Study: NCT00730691

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo-matching capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo-matching capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo-matching capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo-matching capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vortioxetine
Description: Encapsulated vortioxetine immediate release tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vortioxetine
Description: Encapsulated vortioxetine immediate release tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vortioxetine
Description: Encapsulated vortioxetine immediate release tablets

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Duloxetine
Description: Overencapsulated duloxetine capsules
Study: NCT04325321

Intervention type: OTHER
Group type: OTHER
Intervention: Stress reactivity test
Description: The protocol consists of Resting Baseline (BL), Emotion Recall (ER), followed by a Recovery Phase (RP). Heart rate and blood pressure are measured at baseline and then every 5 minutes during ER and RP.~Resting Baseline (BL - 10 min). The participant is instructed to rest quietly.~Emotion Recall (ER - 5-10 min). The participant is instructed to think about the incident associated with the onset of their cardiac event and bring to mind details of the incident. When the participants have the incident clearly in mind, they are instructed to relate the incident and their experience out loud; frequent questions to re-elicit the emotion are asked.~Recovery Phase (RP - 20 min). Upon completion of RP, the catheter is removed and participants are de-instrumented. Blood samples for plasma catecholamines, assessments of heart rate variability, and echocardiograms are performed 10-min into BL, 10-min into ER, and 18 minutes into RP.
Study: NCT02716311

Intervention type: DRUG
Group type: OTHER
Intervention: Afatinib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Afatinib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab
Study: NCT00052221

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Epoetin alfa

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT01488435

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Cow's milk
Description: Powdered whole cow's milk

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Follow-On Formula
Description: Powdered Follow-On Formula with added long-chain Polyunsaturated fatty acid, prebiotics, and polysaccharide
Study: NCT03580915

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Functional Literacy Program
Description: The intervention will be provided twice weekly in 2-hour sessions, over 8 weeks. The 16 intervention sessions will provide the opportunity for participants to learn functional literacy skills to (1) manage an apartment, (2) access community resources, (3) manage finances, (4) access free recreational activities. All sessions will address literacy skills needed to complete basic daily life activities in the home and community environments. Literacy skills will first be learned and practiced within the supported shelter, and then extended to the community.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care Management Services
Description: The control group will receive the usual housing services without additional intervention.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Usual Care Management Services
Description: The control group will receive the usual housing services without additional intervention.
Study: NCT03214588

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-831
Description: TAK-831 tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-831
Description: TAK-831 tablets

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: TAK-831 Placebo
Description: TAK-831 placebo matching tablets
Study: NCT01958294

Intervention type: DEVICE
Group type: OTHER
Intervention: MICHI Neuroprotection System
Study: NCT02065804

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Bupivacaine
Description: injection, once, 5 min
Study: NCT03852693

Intervention type: OTHER
Intervention: Histopathological review
Description: Histopathological review

Intervention type: OTHER
Intervention: Histopathological review
Description: Histopathological review
Study: NCT01252303

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nutrisystem
Description: Nutrisystem meal replacements for 12 weeks
Study: NCT01634178

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apremilast
Description: Tablet for oral administration
Study: NCT02570958

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indocyanine Green
Description: In the operating room ENB will be used to locate the targeted lung tumor. Once the tumor is located, the surgeon will advance a bronchoscope to the tumor, a needle will be passed through the bronchoscope, and the tumor will be injected with 100-150 micro liters of ICG solution at 0.125mg/mL concentration. The tumor is expected to fluoresce using the da Vinci Firefly robotic camera, giving off a bright green hue. Wedge resection of the fluorescent part of the lung will then be performed. The excised specimen will be sent for immediate pathologist analysis. If the tumor is found within the specimen, and the specimen margins are free of tumor cells, then the procedure will be completed. If the tumor cannot be targeted or visualized, or if the tumor is not found in the pathological specimen, or if the margins of the specimen contain tumor cells, then a formal anatomical lobectomy or segmental resection of the lung will be performed to ensure that the tumor is completely excised.
Study: NCT00864396

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prevacid
Description: 30mg of Lansoprazole twice daily (or placebo)for eight weeks.
Study: NCT01837914

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Maxillary expansion

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Maxillary expansion

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Adenotonsillectomy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Adenotonsillectomy
Study: NCT03158727

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cx611
Description: Two intravenous infusions, one on day 1 and another one on day 3.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Two intravenous infusions, one on day 1 and another one on day 3.
Study: NCT01862601

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: JetTouch Needle-free injection system
Description: Needle-free injection system believed to provide consistent and reliable delivery of material to the bladder wall.
Study: NCT02153203

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Prevent-Teach-Reinforce Model
Description: Implementation of the model once to twice per week over a period of 8 weeks

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Individual Parent Training Session
Description: One 2- to 3-hour individual parent training session on the assessment and treatment of problem behavior
Study: NCT01358071

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NGR-hTNF
Description: NGR-hTNF: 0.8 mcg/m² as 60 minutes intravenous infusion weekly or every 3 or 4 weeks until confirmed evidence of disease progression or unacceptable toxicity occurs

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegylated liposomal doxorubicin
Description: 50 mg/m² iv every 4 weeks until confirmed evidence of disease progression

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pegylated liposomal doxorubicin
Description: 50 mg/m² iv every 4 weeks until confirmed evidence of disease progression

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: 60 mg/m² iv every 3 weeks for a maximum of 8 cycles

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Doxorubicin
Description: 60 mg/m² iv every 3 weeks for a maximum of 8 cycles
Study: NCT04025476

Intervention type: DRUG
Intervention: Steroids
Description: IV and oral steroids
Study: NCT01680237

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive behavior therapy
Description: Treatment covers psychoeducation on the nature of anxiety and panic, interoceptive and intensified situational exposure exercises as well as identification and correction of maladaptive thoughts about anxiety and its consequences.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Exposure in-vivo
Description: Treatment covers psychoeducation on the nature of anxiety and panic, interoceptive and intensified situational exposure exercises.
Study: NCT01844479

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: diabetic foot orthotic
Description: The Dynamic Foot Orthosis (DFO) is designed with a rolling link mechanism at the distal 3rd to reduce sliding friction at the metatarsal heads in addition to decreasing compressive forces. The relative sliding motion of two compliant surfaces over each other allows some deformation horizontally and lowers frictional resistance. The DFO addresses the friction element by accommodating the normal sliding and rolling motion at the distal 3rd of the foot during gait. Additionally, the DFO has a silicone layer at the metatarsal head and the remainder of the anterior section made of 2 separated orthotic layers that slide over each other. This provides an articulating surface to provide a relative motion between the orthotic segments while transmitting load.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard innersole
Study: NCT03932409

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: prior to VCB: 200mg IV given one week (7 days) before radiation~after VCB: 200mg IV on day 1 of a 21 day cycle prior to chemotherapy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Vaginal cuff brachytherapy (VCB)
Description: Treatment should commence within 12 weeks of the surgery/hysterectomy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: after VCB, Paclitaxel IV on days 1,8 and 15 of a 21 day cycle for 3 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: after VCB, Carboplatin IV on day 1 of a 21 day cycle for 3 cycles
Study: NCT02492711

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Physician's choice of chemotherapy.
Description: Capecitabine (Xeloda®):1000 mg/m2 BID for 14 days in a 21-day cycle, or Eribulin (Halaven®): 1.4 mg/m2 on days 1 and 8 of a 21-day cycle, or Gemcitabine (Gemzar®): 1000 mg/m2 on days 1 and 8 of a 21-day cycle, or Vinorelbine (Navelbine®): 25-30 mg/m2 on days 1 and 8 of a 21-day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Physician's choice of chemotherapy.
Description: Capecitabine (Xeloda®):1000 mg/m2 BID for 14 days in a 21-day cycle, or Eribulin (Halaven®): 1.4 mg/m2 on days 1 and 8 of a 21-day cycle, or Gemcitabine (Gemzar®): 1000 mg/m2 on days 1 and 8 of a 21-day cycle, or Vinorelbine (Navelbine®): 25-30 mg/m2 on days 1 and 8 of a 21-day cycle

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Physician's choice of chemotherapy.
Description: Capecitabine (Xeloda®):1000 mg/m2 BID for 14 days in a 21-day cycle, or Eribulin (Halaven®): 1.4 mg/m2 on days 1 and 8 of a 21-day cycle, or Gemcitabine (Gemzar®): 1000 mg/m2 on days 1 and 8 of a 21-day cycle, or Vinorelbine (Navelbine®): 25-30 mg/m2 on days 1 and 8 of a 21-day cycle
Study: NCT01177215

Intervention type: PROCEDURE
Intervention: Thoracic Surgery
Description: Wedge Resection Segmental Resection Lobectomy
Study: NCT03088904

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: FluMist® Quadrivalent
Description: LAIV4 vaccine dosage is 0.2 mL. Vaccine will be administered as an intranasal spray. Each sprayer contains a single dose of FluMist® Quadrivalent; approximately one-half of the contents should be administered into each nostril. 0.1 mL (i.e., half of the dose from a single FluMist sprayer) is administered into each nostril while the recipient is in an upright position. Insert the tip of the sprayer just inside the nose and rapidly depress the plunger until the dose-divider clip stops the plunger. The dose divider clip is removed from the sprayer to administer the second half of the dose (0.1 mL) into the other nostril.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Fluzone® Quadrivalent vaccine
Description: IIV4 vaccine will be administered as a 0.5 mL dose, with a sterile, disposable syringe and needle by IM injection into the deltoid muscle.
Study: NCT04080232

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: lung MRI
Description: lung MRI (1.5T Siemens Aera) using the following sequences: 3D Fast gradient-echo pulse sequences with ultra-short echo time (UTE), acquisitions at end-inspiration breath hold, end-expiration breath hold, and free-breathing using an echonavigator positioned on the diaphragm, acquisitions using routine pulse sequences (SSFP, T2FSE) and the administration of oxygen during the MRI: O2 will be administered at 15L/min during 6 minutes.
Study: NCT03935048

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Higher protein, low glycemic load diet
Description: All dietary treatments will be designed to be isoenergetic within individual participants. Energy content of the diets will be individualized to ensure weight maintenance throughout the dietary intervention period using the Harris Benedict equation x 1.35. Glycemic load for the treatment groups will be calculated using the following equation:~Glycemic Load = Glycemic Index x Grams of carbohydrates/100. Potatoes, processed potato products, and control carbohydrate foods will be provided.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Higher protein, low glycemic load diet
Description: All dietary treatments will be designed to be isoenergetic within individual participants. Energy content of the diets will be individualized to ensure weight maintenance throughout the dietary intervention period using the Harris Benedict equation x 1.35. Glycemic load for the treatment groups will be calculated using the following equation:~Glycemic Load = Glycemic Index x Grams of carbohydrates/100. Potatoes, processed potato products, and control carbohydrate foods will be provided.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Higher protein, low glycemic load diet
Description: All dietary treatments will be designed to be isoenergetic within individual participants. Energy content of the diets will be individualized to ensure weight maintenance throughout the dietary intervention period using the Harris Benedict equation x 1.35. Glycemic load for the treatment groups will be calculated using the following equation:~Glycemic Load = Glycemic Index x Grams of carbohydrates/100. Potatoes, processed potato products, and control carbohydrate foods will be provided.
Study: NCT02098538

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Regorafenib
Description: All eligible patients will receive a starting regorafenib dose of 120 mg daily taken orally for 3 weeks in a 4-week cycle. Patients for whom regorafenib dose reduction was not performed or required may have their treatment dose increased to the FDA-approved dose of 160 mg daily orally for 3 weeks in a 4-week cycle in cycle #2 or beyond (this is not mandatory). RECIST v1.1 tumor assessments will be made at baseline (CT or MRI) and then approximately every 2 cycles (or every 8 weeks (+/- 1 week)). After 10 months, imaging will be done every 3 cycles (or every 12 weeks (+/- 1 week)). Patients may remain on study until progression of disease or unacceptable toxicity
Study: NCT03445845

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Secukinumab
Description: Secukinumab : 150 mg per week for 5 weeks, and then every month by subcutaneous injection

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TNF blocker
Description: TNF blocker (originator or biosimilar) :~* infliximab: 5mg/kg per IV infusion at weeks 0, 2, 6, and then every 6 weeks,~* etanercept: 50mg per week in subcutaneous injection,~* adalimumab: 40mg every other week in subcutaneous injection,~* certolizumab: 400mg every other week 3 times, and then 200mg every other week or 400mg per month in subcutaneous injections,~* golimumab: 50mg every month in subcutaneous injection, in case of overweight (\>100kg) an inadequate response, 100mg every month is allow.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: blood specimen
Description: Blood specimen at each visits for measurement of bDMARS blockers concentration and anti-drug antibody concentration

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: blood specimen
Description: Blood specimen at each visits for measurement of bDMARS blockers concentration and anti-drug antibody concentration
Study: NCT01527266

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Carbohydrate drink
Description: sucrose beverage

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Carbohydrate drink
Description: sucrose beverage

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo mouth rinse
Description: placebo; non-caloric sweetened beverage for use as a mouth rinse
Study: NCT01424163

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Multiple Dose
Description: Part B
Study: NCT04128033

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Puncture of the RP6 point
Description: Puncture of RP6 San Yin Jiao point, located just behind the posterior edge of the tibia 3 cm above the end of the inner malleolus.
Study: NCT01527266

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo mouth rinse
Description: placebo; non-caloric sweetened beverage for use as a mouth rinse